Strategies to Secure Access to Generic Hepatitis C Medicines

Overcoming patent and regulatory barriers to secure access to generic hepatitis C medicines

Médecins Sans Frontières / Doctors Without Borders (MSF) Briefing Document, May 2015

9 pp. 985 kB:

MSF is in the process of starting to treat people who are living with hepatitis C virus (HCV) in at least nine countries, and therefore is in need of affordable access to direct acting antiviral (DAA) treatments, including those marketed by Gilead Sciences (Gilead) and Bristol-Myers Squibb (BMS). This document offers guidance to policy makers to enable access to these medicines to scale up HCV treatment.

(Visited 62 times, 1 visits today)
This entry was posted in Essential Medicines, General, Other Infectious Diseases. Bookmark the permalink.